30th Oct 2014 10:48
LONDON (Alliance News) - GW Pharmaceuticals PLC on Thursday said it has started a Phase 2/3 clinical trial on Epidiolex for the treatment of Dravet syndrome.
Dravet is a treatment-resistant form of childhood epilepsy.
"The results of our open-label trial of Epidiolex in children with Dravet syndrome have been very encouraging and we are excited to begin this important placebo-controlled clinical trial," stated Orrin Devinsky, Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine, and principal investigator of the trial.
GW said it anticipates starting an additional Phase 3 trial in Dravet syndrome in the first quarter of next year, along with the second part of the Phase 2/3 trial. It also intends to start two Phase 3 clinical trials on Lennox-Gastaut syndrome, another form of childhood epilepsy, in the first quarter of 2015.
GW shares were down 1.3% to 367 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L